GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » MDxHealth SA (NAS:MDXH) » Definitions » Shiller PE Ratio

MDxHealth (MDxHealth) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2008. Start your Free Trial

What is MDxHealth Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


MDxHealth Shiller PE Ratio Historical Data

The historical data trend for MDxHealth's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MDxHealth Shiller PE Ratio Chart

MDxHealth Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MDxHealth Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MDxHealth's Shiller PE Ratio

For the Diagnostics & Research subindustry, MDxHealth's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MDxHealth's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where MDxHealth's Shiller PE Ratio falls into.



MDxHealth Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

MDxHealth's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, MDxHealth's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.39/128.2922*128.2922
=-0.390

Current CPI (Dec. 2023) = 128.2922.

MDxHealth Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200412 0.000 81.415 0.000
200512 0.000 83.764 0.000
200612 0.000 85.142 0.000
200712 0.000 87.768 0.000
200812 0.000 90.077 0.000
200906 -0.673 89.909 -0.960
200912 -0.888 90.315 -1.261
201006 -0.463 92.119 -0.645
201012 -0.375 93.120 -0.517
201106 -0.290 95.508 -0.390
201112 -0.230 96.360 -0.306
201206 -0.291 97.659 -0.382
201212 -0.241 98.511 -0.314
201306 -0.230 99.215 -0.297
201312 -0.310 99.462 -0.400
201406 -0.230 99.482 -0.297
201412 -0.210 99.086 -0.272
201506 -0.120 100.107 -0.154
201512 -0.230 100.572 -0.293
201606 -0.170 102.267 -0.213
201612 -0.120 102.614 -0.150
201706 0.010 103.902 0.012
201712 -0.260 104.804 -0.318
201806 -0.270 106.063 -0.327
201812 -0.290 107.252 -0.347
201906 -0.240 107.896 -0.285
201912 -0.450 108.065 -0.534
202006 -0.180 108.540 -0.213
202012 -0.160 108.511 -0.189
202106 -0.120 110.305 -0.140
202109 -0.600 111.543 -0.690
202112 -0.600 114.705 -0.671
202203 -0.500 118.620 -0.541
202206 -0.700 120.948 -0.743
202209 -0.800 124.120 -0.827
202212 -0.800 126.578 -0.811
202303 -0.500 126.528 -0.507
202306 -0.300 125.973 -0.306
202309 -0.400 127.083 -0.404
202312 -0.390 128.292 -0.390

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MDxHealth  (NAS:MDXH) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


MDxHealth Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of MDxHealth's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MDxHealth (MDxHealth) Business Description

Traded in Other Exchanges
N/A
Address
Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.